Total Payments
$419,950
2024 Payments
$40,523
Companies
54
Transactions
500
Medicare Patients
16,615
Medicare Billing
$3.2M
Payment Breakdown by Category
Other$217,413 (51.8%)
Consulting$128,265 (30.5%)
Research$53,921 (12.8%)
Travel$10,686 (2.5%)
Food & Beverage$9,041 (2.2%)
Education$623.76 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $209,933 | 124 | 50.0% |
| Consulting Fee | $128,265 | 59 | 30.5% |
| Unspecified | $53,921 | 47 | 12.8% |
| Travel and Lodging | $10,686 | 25 | 2.5% |
| Food and Beverage | $9,041 | 233 | 2.2% |
| Honoraria | $7,480 | 2 | 1.8% |
| Education | $623.76 | 10 | 0.1% |
Payments by Type
General
$366,029
453 transactions
Research
$53,921
47 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $193,007 | 166 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $94,132 | 59 | $0 (2024) |
| Lilly USA, LLC | $69,227 | 52 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $9,961 | 10 | $0 (2024) |
| WHITEHALL INTERNATIONAL INC | $7,700 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $7,278 | 18 | $0 (2024) |
| Incyte Corporation | $5,009 | 7 | $0 (2024) |
| Eli Lilly and Company | $4,953 | 2 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $4,785 | 11 | $0 (2024) |
| Foundation Medicine, Inc. | $4,480 | 5 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40,523 | 70 | PFIZER INC. ($32,446) |
| 2023 | $58,952 | 90 | PFIZER INC. ($39,348) |
| 2022 | $59,742 | 73 | PFIZER INC. ($34,592) |
| 2021 | $91,702 | 53 | Lilly USA, LLC ($31,598) |
| 2020 | $82,368 | 58 | Lilly USA, LLC ($26,450) |
| 2019 | $51,464 | 79 | PFIZER INC. ($23,386) |
| 2018 | $20,635 | 41 | PFIZER INC. ($15,751) |
| 2017 | $14,563 | 36 | PFIZER INC. ($13,308) |
All Payment Transactions
500 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $18.33 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: Oncology | ||||||
| 11/25/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $20.65 | General |
| Category: HEMATOLOGY | ||||||
| 11/06/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: CELLT | ||||||
| 10/30/2024 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | Cash or cash equivalent | $460.10 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | In-kind items and services | $197.18 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,886.00 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.88 | General |
| Category: Hematology | ||||||
| 10/24/2024 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $2,548.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $3,640.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Tempus AI, Inc | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $19.73 | General |
| 10/13/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,250.00 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $26.75 | General |
| Category: Oncology | ||||||
| 10/03/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $90.85 | General |
| 09/23/2024 | PFIZER INC. | LORBRENA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,750.00 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | PFIZER INC. | XALKORI (Drug), MEKTOVI | — | In-kind items and services | $940.00 | Research |
| Study: XALKORI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 09/09/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $27.97 | General |
| 09/08/2024 | PFIZER INC. | LORBRENA (Drug) | Travel and Lodging | In-kind items and services | $497.08 | General |
| Category: ONCOLOGY | ||||||
| 09/08/2024 | PFIZER INC. | LORBRENA (Drug) | Food and Beverage | In-kind items and services | $75.73 | General |
| Category: ONCOLOGY | ||||||
| 09/07/2024 | PFIZER INC. | LORBRENA (Drug) | Food and Beverage | In-kind items and services | $44.10 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LORLATINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $16,610 | 15 |
| LUNG ONCOLOGY CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,670 | 8 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $8,750 | 1 |
| ENCORAFENIB CRIZOTINIB LORLATINIB MULTI PRODUCT DACOMITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $5,870 | 4 |
| ENCORAFENIB DACOMITINIB BINIMETINIB MULTI PRODUCT LORLATINIB CRIZOTINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,530 | 2 |
| PHASE 12 STUDY OF PF06463922 AN ALKROS1 TYROSINE KINASE INHIBITOR IN PATIENTS WITH ADVANCED NONSMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS | PFIZER INC. | $3,323 | 7 |
| ENCORAFENIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,720 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,047 | 1 |
| XALKORI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| STARTRK 2 RXDX 101 02, ALKA ALKA 372 001 and STARTRK 1 RXDX 101 01 | F. Hoffmann-La Roche AG | $872.34 | 1 |
| A PHASE 3 RANDOMIZED OPENLABEL STUDY OF LORLATINIB PF06463922 MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRSTLINE TREATMENT OF PATIENTS WITH ADVANCED ALKPOSITIVE NONSMALL CELL LUNG CANCER | PFIZER INC. | $250.00 | 1 |
| A Phase 11b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib RXDX-101 in Children and Adolescents with Recurrent or Refractory Solid Tumors and Primary CNS Tumors, with or without TRK, ROS1, or ALK Fusions, An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult | F. Hoffmann-La Roche AG | $137.37 | 1 |
| A PHASE I OPEN LABEL STUDY OF GSK3359609 ADMINISTERED ALONE AND IN COM | GlaxoSmithKline, LLC. | $83.33 | 1 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS 986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors | E.R. Squibb & Sons, L.L.C. | $65.00 | 1 |
| A PHASE 1A-1B TRIAL INVESTIGATING THE CSF-1R INHIBITOR LY3022855 IN COMBINATION WITH DURVALUMAB -MEDI4736- OR TREMELIMUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Eli Lilly and Company | $52.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 73 | 4,476 | 180,824 | $2.7M | $1.4M |
| 2022 | 67 | 3,789 | 100,247 | $1.2M | $543,996 |
| 2021 | 68 | 4,167 | 100,550 | $1.4M | $629,983 |
| 2020 | 71 | 4,183 | 102,433 | $1.6M | $671,126 |
Total Patients
16,615
Total Services
484,054
Medicare Billing
$3.2M
Procedure Codes
279
All Medicare Procedures & Services
279 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 29,280 | $1.1M | $689,857 | 63.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 33 | 5,400 | $158,520 | $99,927 | 63.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 211 | 716 | $210,113 | $88,334 | 42.0% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 63 | 88,500 | $178,500 | $76,549 | 42.9% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 37 | 31,740 | $126,960 | $74,202 | 58.4% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 12 | 2,010 | $124,040 | $72,106 | 58.1% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 80 | 395 | $150,735 | $35,872 | 23.8% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 29 | 92 | $49,619 | $29,995 | 60.5% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 300 | $49,500 | $24,741 | 50.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 186 | 277 | $56,959 | $24,237 | 42.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 375 | 1,381 | $25,155 | $14,161 | 56.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 381 | 1,651 | $24,774 | $13,794 | 55.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 377 | 1,704 | $24,246 | $12,819 | 52.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 156 | 204 | $29,679 | $11,890 | 40.1% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 12 | 69 | $52,716 | $11,720 | 22.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 71 | 71 | $24,282 | $11,203 | 46.1% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 26 | 130 | $9,100 | $9,065 | 99.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 98 | 191 | $36,896 | $8,295 | 22.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 70 | 377 | $32,639 | $7,688 | 23.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 65 | 65 | $16,835 | $7,498 | 44.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 19 | 106 | $25,237 | $5,393 | 21.4% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 32 | 117 | $22,956 | $5,084 | 22.1% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 148 | 317 | $7,608 | $4,212 | 55.4% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 67 | 238 | $7,560 | $3,871 | 51.2% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 72 | 389 | $6,800 | $3,432 | 50.5% |
About Dr. Todd Bauer, MD
Dr. Todd Bauer, MD is a Hematology & Oncology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1336296136.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Todd Bauer, MD has received a total of $419,950 in payments from pharmaceutical and medical device companies, with $40,523 received in 2024. These payments were reported across 500 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($209,933).
As a Medicare-enrolled provider, Bauer has provided services to 16,615 Medicare beneficiaries, totaling 484,054 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 279 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Nashville, TN
- Active Since 01/04/2007
- Last Updated 07/27/2012
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1336296136
Products in Payments
- LORBRENA (Drug) $152,994
- Vitrakvi (Drug) $94,008
- BRAFTOVI (Drug) $15,262
- RETEVMO (Drug) $10,879
- INC280 (Drug) $8,750
- MEKTOVI (Drug) $5,973
- OPDIVO (Biological) $4,837
- FOUNDATIONACT (Device) $4,480
- LIBTAYO (Biological) $2,667
- Non-Covered Product (Drug) $2,130
- PDR001 (Drug) $1,047
- ROZLYTREK (Biological) $1,010
- XALKORI (Drug) $940.00
- KEYTRUDA (Biological) $467.70
- FERAHEME (Drug) $429.01
- VENCLEXTA (Drug) $265.62
- Epkinly (Drug) $250.00
- UKONIQ (Drug) $249.23
- Orserdu (Drug) $241.33
- Enhertu (Drug) $222.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Nashville
Dr. Jonathan Abbas, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Kent Shih, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Alan Tan, M.d, M.D
Hematology & Oncology — Payments: $1.0M
Hematology & Oncology $1.0M
Brian Rini, Md, MD
Hematology & Oncology — Payments: $685,999
Hematology & Oncology $685,999
Jesus Berdeja, M.d, M.D
Hematology & Oncology — Payments: $572,989
Hematology & Oncology $572,989
Dr. Krish Patel, M.d, M.D
Hematology & Oncology — Payments: $568,657
Hematology & Oncology $568,657